Drugs / TQB3217
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07291050 | Dec 2025 → Dec 2026 expected | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
聚焦肿瘤治疗领域，中国生物制药还有TQB2210（FGFR2b单抗）、TQB3217（USP1抑制剂）、TQB3122（PARP1抑制剂）、LM-168（CTLA-4单抗）首次获批临床。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3217 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07291050 ↗ |
| Known as | TQB3217 Tablets | “TQB3217 Tablets are ubiquitin specific peptidase 1(USP1)-t inhibitor.” NCT07291050 ↗ |
| Action | Inhibit | “USP1)-t inhibitor” NCT07291050 ↗ |
| Route | Oral | “recommended to be taken orally” NCT07291050 ↗ |